| Literature DB >> 32455691 |
Joanna Teul1, Stanisław Deja2, Katarzyna Celińska-Janowicz1, Adam Ząbek3, Piotr Młynarz3, Piotr Barć4, Adam Junka5, Danuta Smutnicka5, Marzenna Bartoszewicz5, Jerzy Pałka6, Wojciech Miltyk1.
Abstract
Bacterial wound infections are a common problem associated with surgical interventions. In particular, biofilm-forming bacteria are hard to eradicate, and alternative methods of treatment based on covering wounds with vascularized flaps of tissue are being developed. The greater omentum is a complex organ covering the intestines in the abdomen, which support wound recovery following surgical procedures and exhibit natural antimicrobial activity that could improve biofilm eradication. We investigated changes in rats' metabolome following Klebsiella pneumoniae infections, as well as the greater omentum's ability for Klebsiella pneumoniae biofilm eradication. Rats received either sterile implants or implants covered with Klebsiella pneumoniae biofilm (placed in the peritoneum or greater omentum). Metabolic profiles were monitored at days 0, 2, and 5 after surgery using combined proton nuclear magnetic resonance (1H NMR) and high performance liquid chromatography quadrupole time-of-flight tandem mass spectrometry (LC-QTOF‑MS) measurements of urine samples followed by chemometric analysis. Obtained results indicated that grafting of the sterile implant to the greater omentum did not cause major disturbances in rats' metabolism, whereas the sterile implant located in the peritoneum triggered metabolic perturbations related to tricarboxylic acid (TCA) cycle, as well as choline, tryptophan, and hippurate metabolism. Presence of implants colonized with Klebsiella pneumoniae biofilm resulted in similar levels of metabolic perturbations in both locations. Our findings confirmed that surgical procedures utilizing the greater omentum may have a practical use in wound healing and tissue regeneration in the future.Entities:
Keywords: Klebsiella pneumoniae; implants; metabolomics; microbial biofilm eradication; surgery
Year: 2020 PMID: 32455691 PMCID: PMC7281169 DOI: 10.3390/pathogens9050399
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1The number of bacteria left on the implant withdrawn from rats of IO (infected omentum) (blue dots) and IP (infected peritoneum) (red boxes) groups according to the day of experiment. Data are presented as mean and standard error.
Figure 2Principal component analysis (PCA) (a–c) models for all samples and day 0–5 obtained for each technique, and partial least squares discriminant analysis (PLS-DA) (c,d) models for all groups and days 0–5 obtained for each technique. (a,d) for positive electrospray ionization mode (ESI(+); (b) and (e) for negative electrospray ionization mode (ESI (-)); (c,f) for proton nuclear magnetic resonance (1H NMR). Models were obtained for the following number of variables: ESI(+)—319 variables, ESI(-)—382 variables, 1H NMR—22 variables. R and Q parameters are given for the two first components. p-value for ANOVA of the cross-validated residuals (CV ANOVA) is reported. Investigated groups are marked as follows: group IO (infected omentum)—red squares; IP (infected peritoneum)—black squares; SP (sterile peritoneum)—blue squares; SO (sterile omentum)—green diamonds; C (controls)—yellow dots.
Figure 3Plots for 1H NMR data (22 variables) of all samples from day 0 of the experiment. (a) Score plot of PLS-DA model, R = 0.328, Q = 0.206, CV ANOVA p-value = 0.16. (b) Loading plot for PLS-DA (a) with identification of selected variables. (c) Pathway of hippurate biosynthesis. Normalized signal intensities of (d) hippurate, (e) benzoate, and (f) glycine, quantified using 1H NMR spectroscopy. Data in panels (d–f) are presented as mean and standard error.
Figure 4PLS-DA models for ESI(+) data (319 variables) of groups of samples from day 0 of the experiment: (a) sterile omentum vs. controls; (b) sterile peritoneum vs. controls; (c) sterile implants (omentum and peritoneum) vs. controls; (d) infected omentum vs. controls; (e) infected peritoneum vs. controls; (f) colonized implants (infected omentum and peritoneum) vs. controls; (g) infected omentum vs. sterile omentum; (h) infected peritoneum vs. sterile peritoneum; (i) colonized implants (infected omentum and peritoneum) vs. sterile implants (omentum and peritoneum). R and Q parameters are given for the two first components, and p-values for CV ANOVA for the presented models are found in Table 1.
Parameters of PLS-DA models presented in Figure 4 obtained for ESI(+) data. R and Q parameters for the two first components. p-values are given for CV ANOVA.
| Figure | Comparison | CV ANOVA | Model Significance | ||
|---|---|---|---|---|---|
| SO vs. C | 0.976 | 0.804 | 2.40 × 10−1 | No | |
| SP vs. C | 0.999 | 0.93 | 1.20 × 10−2 | ||
| SO + SP vs. C | 0.955 | 0.739 | 1.17 × 10−2 | ||
| IO vs. C | 0.984 | 0.903 | 9.04 × 10−4 | ||
| IP vs. C | 0.974 | 0.792 | 1.69 × 10−3 | ||
| IO + IP vs. C | 0.963 | 0.913 | 6.44 × 10−9 | ||
| IO vs. SO | 0.975 | 0.773 | 1.84 × 10−2 | ||
| IP vs. SP | 0.954 | 0.354 | 3.57 × 10−1 | No | |
| IO + IP vs. SO + SP | 0.790 | 0.382 | 3.50 × 10−2 |
Figure 5Number of significant metabolites (the variable importance in the projection values (VIP) > 1, p-value < 0.05) found in a merged dataset of 1H NMR- and LC–MS-identified features: (a) omentum, (b) peritoneum.
List of identified metabolites significantly different between the studied groups of infected omentum versus sterile omentum (IO vs. SO), infected peritoneum versus sterile peritoneum (IP vs. SP), infected omentum versus infected peritoneum (IO vs. IP), and sterile omentum versus sterile peritoneum (SO vs. SP).
| Day | d0 | d2 | d5 | d0 | d2 | d5 | d0 | d2 | d5 | d0 | d2 | d5 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Groups | IO_SO | IO_SO | IO_SO | IP_SP | IP_SP | IP_SP | IO_IP | IO_IP | IO_IP | SO_SP | SO_SP | SO_SP | ||||||||||||
| N-acetylaspartate | 5% | - | 33% | - | −33% | - | 12% | - | 7% | - | 18% | - | −22% | - | −12% | - | −14% | - | −17% | - | −30% | - | 52% | - |
| L−Lactic acid | −88% | ** | −83% | - | 138% | - | 89% | * | 30% | - | 98% | - | −12% | - | 302% | - | 16% | - | 1259% | ** | 1245% | ** | 209% | - |
| Formic acid | −38% | - | −83% | ** | −79% | - | −63% | ** | −22% | - | 166% | - | 13% | - | −5% | - | 35% | - | −55% | - | 36% | - | 325% | * |
| Acetic acid | −82% | ** | −93% | - | −62% | - | 18% | * | −7% | - | 271% | - | 11% | - | 208% | - | 40% | - | 575% | ** | 424% | * | 569% | * |
| Pyruvic acid | −15% | * | −38% | - | −14% | - | 8% | - | 2% | - | 42% | - | 15% | - | 26% | * | 58% | - | 62% | ** | 66% | * | 70% | * |
| Citric acid | 14% | - | 474% | - | 313% | - | 1% | - | 1% | - | −36% | - | 20% | - | 18% | - | 4% | - | 36% | * | 30% | - | −77% | * |
| alpha-ketoglutaric acid | 60% | - | 68% | - | 53% | - | 8% | - | 19% | - | −2% | - | 45% | - | 52% | - | 84% | * | 76% | ** | 60% | - | 19% | - |
| cis-Aconitic acid | 7% | - | 6% | - | 159% | - | −23% | - | 4% | - | −7% | - | 26% | - | 6% | - | 30% | - | −19% | - | −3% | - | 12% | - |
| trans-Aconitic acid | 18% | * | 33% | - | −27% | - | 8% | - | −3% | - | 7% | - | 0% | - | 3% | - | −7% | - | −15% | * | −10% | - | −3% | - |
| Succinic acid | −38% | - | −66% | - | −16% | - | −24% | - | −9% | - | 27% | - | 52% | * | 50% | * | 136% | * | 65% | - | 61% | - | 263% | * |
| Succinic acid semialdehyde | −20% | - | −10% | - | 178% | * | 69% | - | 45% | - | 10% | - | 21% | - | 43% | - | 81% | - | 155% | * | 128% | - | −29% | - |
| Fumaric acid | 159% | - | 331% | - | 387% | - | −14% | - | −6% | - | −27% | - | 40% | - | 57% | - | −23% | - | −39% | - | −22% | - | −69% | * |
| Malic acid | 42% | - | 64% | * | 25% | - | −2% | - | 2% | - | −29% | - | 15% | - | 58% | * | 53% | - | −21% | - | −2% | - | −12% | - |
| Pyroglutamic acid | −11% | - | 38% | - | 21% | - | 4% | - | −10% | - | −13% | - | −26% | - | 14% | - | 51% | - | −14% | - | −25% | - | 9% | - |
| L-Alanine | −49% | ** | −89% | - | −63% | ** | −9% | - | 9% | - | 138% | - | 8% | - | 40% | - | 0% | - | 59% | * | 152% | * | 514% | * |
| Tryptophyl-Glutamate | 14% | - | −12% | - | −22% | - | −3% | - | 29% | - | −4% | - | 46% | - | 31% | - | 42% | - | 25% | - | 92% | * | 75% | - |
| Indoxyl sulfate | −18% | - | −17% | - | 5% | - | −30% | - | 68% | - | 1% | - | 18% | - | −16% | - | 37% | - | 1% | - | 71% | - | 33% | - |
| Benzoic acid | −83% | ** | −76% | - | −21% | - | 33% | - | 8% | - | 70% | - | 44% | - | 258% | * | 0% | - | 1419% | ** | 857% | ** | 173% | * |
| Glycine | −74% | ** | −68% | - | 38% | - | 39% | * | −7% | - | 39% | - | 8% | - | 155% | - | −2% | - | 639% | ** | 426% | * | 113% | - |
| Hippuric acid | 310% | ** | 877% | - | 442% | - | −11% | - | −13% | - | −56% | - | −21% | - | −21% | - | 10% | - | −93% | ** | −81% | ** | −91% | * |
| Choline | −8% | - | −67% | * | −7% | - | 54% | - | 4% | - | 228% | - | 45% | - | −24% | * | 22% | - | 145% | * | 139% | * | 333% | - |
| Betaine | 7% | - | −34% | - | −19% | - | −18% | - | −8% | - | −5% | - | 15% | - | −4% | - | 46% | - | 21% | - | 24% | * | 5% | - |
| Creatinine | 48% | - | 5% | - | 82% | - | 4% | - | −20% | - | 8% | - | −3% | - | 18% | - | −16% | - | −32% | - | −11% | - | −50% | * |
| Phosphorylcholine | 52% | - | 36% | - | 243% | - | −32% | - | −27% | - | −49% | - | 2% | - | 14% | - | 27% | - | −55% | - | −39% | - | −81% | - |
| Tetrahydrofolic acid | 1% | - | 1% | - | 66% | - | 139% | * | −4% | - | 10% | - | −34% | - | −9% | - | 48% | - | 56% | - | −14% | - | −2% | - |
| Isonicotinylglycine | 126% | ** | 75% | - | na | - | −41% | * | −16% | - | −54% | - | 33% | - | 8% | - | −51% | - | −65% | * | −48% | - | na | - |
| Phenylacetylglycine | 55% | - | 38% | - | 1041% | - | −35% | - | 40% | - | −41% | - | 17% | - | −23% | - | −1% | - | −51% | - | −22% | - | −95% | * |
| 3-Hydroxyhippuric acid | 78% | - | 129% | * | 683% | - | 12% | - | −1% | - | 65% | - | −2% | - | 4% | * | 21% | - | −39% | - | −55% | - | −74% | - |
| Tetrahydrocortisone | 16% | - | 18% | - | −8% | - | 33% | - | 44% | * | −7% | - | −18% | - | −13% | - | −4% | - | −6% | - | 6% | - | −2% | - |
| Dihydrocortisol | 56% | - | 34% | - | −47% | - | 5% | - | 20% | - | −46% | - | 9% | - | −18% | - | −6% | - | −27% | - | −27% | - | −4% | - |
| Taurine | 12% | - | −23% | - | 80% | - | −30% | - | 26% | - | −12% | - | −1% | - | −24% | - | −22% | - | −38% | - | 24% | - | −62% | * |
| Indolylacryloylglycine | -4% | - | 7% | - | 103% | - | −18% | - | −17% | - | −10% | - | 46% | - | 41% | - | 36% | - | 25% | - | 9% | - | −40% | - |
| kamlolenic acid | 143% | - | −8% | - | 25% | - | 35% | - | 34% | - | 160% | - | 19% | - | 7% | - | −4% | - | −34% | - | 56% | - | 99% | - |
| Xylitol (+Ribitol) | 16% | - | −1% | - | 73% | - | 15% | - | 35% | - | 5% | - | −1% | - | −19% | - | 11% | - | −2% | - | 11% | - | −32% | - |
| Stachyose | 13% | - | −40% | * | −61% | - | 648% | - | 17% | - | −1% | - | −58% | - | −27% | * | −32% | - | 176% | * | 42% | - | 73% | - |
| Phenol sulphate | 10% | - | −8% | - | 60% | - | −46% | * | 6% | - | −52% | * | 34% | - | 0% | - | 11% | - | −34% | - | 16% | - | −66% | * |
| Tyrosol 4-sulfate | 5% | - | −15% | - | −12% | - | −10% | - | −32% | - | −40% | - | −17% | - | 12% | - | 73% | - | −28% | - | −11% | - | 17% | - |
| Pyrocatechol sulphate | −5% | - | 37% | * | −14% | - | −36% | ** | −8% | - | −14% | - | 2% | - | 0% | * | −11% | - | −31% | * | −33% | * | −11% | - |
| Allantoin | 29% | - | 5% | - | 58% | - | 45% | * | 12% | - | −20% | - | 5% | - | 1% | - | 14% | - | 19% | - | 8% | - | −42% | - |
| Caffeic acid 3-sulfate / Caffeic acid 4-sulfate | −13% | - | −1% | - | −15% | - | −24% | * | −15% | - | 36% | - | 10% | - | 30% | - | 5% | - | −4% | - | 11% | - | 69% | - |
| Dihydrocaffeic acid 3-sulfate | 56% | - | 51% | - | −4% | - | −35% | * | −24% | - | −44% | * | 15% | - | 4% | - | 22% | - | −52% | * | −48% | * | −28% | - |
| Ferulic acid | 71% | * | 19% | - | −4% | - | −40% | ** | −4% | - | −34% | - | 0% | - | 0% | - | 35% | - | −65% | * | −20% | - | −7% | - |
| Ferulic acid 4-O-sulfate | 39% | - | 31% | - | 0% | - | −44% | * | −24% | - | −35% | - | −10% | - | 28% | - | 29% | - | −64% | * | −26% | - | −17% | - |
| Dihydroferulic acid | −54% | - | 60% | - | 56% | - | 56% | - | 6% | - | −27% | - | 9% | - | 480% | - | 134% | - | 270% | - | 284% | * | 10% | - |
| Ferrulic acid 4-O-glucuronide | 175% | ** | 31% | - | 159% | - | −18% | - | 10% | - | −75% | - | 17% | - | 4% | - | 41% | - | −65% | - | −13% | - | −86% | - |
| Dihydrocaffeic acid 3-O-glucuronide | 88% | - | 34% | - | 8274% | - | −27% | - | −26% | * | −31% | - | 21% | - | −27% | - | 0% | - | −52% | * | −60% | * | −99% | - |
| Dihydroferulic acid 4-O-glucuronide | 96% | - | 60% | - | 642% | - | −27% | * | −11% | - | −41% | - | 21% | - | −14% | - | 90% | - | −55% | * | −52% | * | −85% | - |
| Dihydroferuloylglycine | 229% | - | −5% | - | 144% | - | −48% | - | 5% | - | −29% | - | 57% | - | 29% | - | 130% | - | −75% | * | 43% | - | −33% | - |
| Urea | 15% | - | −14% | - | 3065% | - | −25% | * | 7% | - | −28% | - | 10% | - | −7% | - | 53% | - | −32% | ** | −12% | - | 15% | - |
| Histamine | 36% | - | 27% | - | 52% | - | −30% | - | 24% | - | −39% | * | 16% | - | 9% | - | 13% | - | −40% | - | 7% | - | −55% | - |
| 17,21-Dihydroxypregnenolone | 78% | - | 91% | - | −3% | - | −9% | - | 121% | - | 11% | - | −7% | - | −24% | - | −25% | - | −53% | - | −13% | - | −14% | - |
| Isohomovanillic acid | 11% | - | 30% | - | −18% | - | −14% | - | 18% | - | −20% | - | 15% | - | 79% | - | 31% | - | −11% | - | 63% | - | 28% | - |
| 4-Hydroxybenzaldehyde | −30% | - | 0% | - | −20% | - | −21% | - | 21% | - | −16% | - | 44% | * | 15% | - | −11% | - | 62% | - | 39% | - | −7% | - |
| 3-Hydroxydodecanedioic acid | −6% | - | −27% | - | −35% | - | −3% | - | 1% | - | −2% | - | 47% | - | 25% | - | 24% | - | 51% | * | 73% | - | 86% | * |
| 3-Hydroxyisoheptanoic acid / Ethyl 2-hydroxyisovalerate | 15% | - | −13% | - | −14% | - | 66% | - | 51% | - | 61% | - | −12% | - | 24% | - | 2% | - | 27% | - | 116% | * | 90% | - |
| O-methoxycatechol-O-sulphate | 10% | - | 7% | - | −17% | - | −47% | ** | 10% | - | −50% | - | 18% | - | −13% | - | −5% | - | −43% | * | −11% | - | −42% | - |
| Trigonelline | 30% | * | −9% | - | 8% | - | −16% | - | −22% | - | −11% | - | 0% | - | 8% | - | 10% | - | −34% | ** | −29% | ** | 0% | - |
| Oxolan-3-one | 35% | * | 20% | * | 3% | - | −10% | - | 9% | - | −6% | - | 11% | - | 8% | * | 10% | - | −26% | * | −2% | - | 1% | - |
| N-Acetyl-7-O-acetylneuraminic acid | 100% | - | −49% | - | 7% | - | −8% | - | −1% | - | 46% | - | 136% | - | −21% | - | 33% | - | 9% | - | 53% | - | 81% | - |
| Ethanol | −2% | - | −32% | - | −9% | - | 19% | - | 3% | - | 65% | - | −10% | - | 2% | - | 38% | - | 3% | - | 1% | - | 42% | * |
| 2-Octenedioic acid / cis-4-Octenedioic acid / trans-3-Octenedioic acid | −7% | - | 40% | - | 74% | - | 152% | * | 19% | - | 24% | - | −17% | - | 2% | - | 44% | - | 126% | * | −14% | - | 2% | - |
| beta-D-Mannosylphosphodecaprenol | −68% | ** | −45% | * | −5% | - | 141% | * | 37% | - | 101% | * | −41% | - | 22% | * | −11% | - | 345% | * | 202% | * | 89% | - |
Percentage change between the two groups was calculated using following equation: 100% * (group 1-group2)/group 2, p-values: * p-value < 0.05; ** p-value < 0.01; - p-value not significant. (n) metabolites found in negative polarity mode; (p) metabolites found in positive polarity mode; (m) metabolites found in 1H NMR; (a) metabolites annotated by MS/MS spectra and MS fragmentation pattern; (b) metabolites annotated putatively by exact mass data and isotopic pattern distribution. Color coding: red- increase in the first comparing to the second group, light blue-decrease in the first comparing to the second, yellow – denotes statistically significant change.
Experiment group coding and number of samples in each group depending on the day of the experiment. Only samples from day 0, 2, and 5 were used for statistical analysis.
| Number of Urine Samples | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Implant | Place of Implant Grafting | Name of the Group | Initial Number of Rats | Day 0 | Day 2 | Day 5 | Day 9 | Day 14 | Day 30 |
| Sterile | Peritoneum | SP | 5 | 5 | 5 | 5 | 3 | 2 | 1 |
| Sterile | Omentum | SO | 5 | 5 | 5 | 4 | 2 | 1 | 1 |
| Colonized | Peritoneum | IP | 10 | 10 | 10 | 8 | 6 | 4 | 2 |
| Colonized | Omentum | IO | 10 | 10 | 10 | 7 | 6 | 4 | 2 |
| - | No surgery | C | 5 | 5 | 5 | 4 | 3 | 2 | 1 |